On April 29, Chia Tai Tianqing, the core enterprise of Sino Biopharm (1177.HK), once again joined hands with the Greater China Cancer Care Foundation (hereinafter referred to as "the Foundation") to officially include the world's first CDK2/4/6 inhibitor, Culmerciclib Capsules (Saitanxin^®), into the Compassionate Corporate Partner NPP Cooperation Agreement, bringing a new treatment option to breast cancer patients in Hong Kong with urgent treatment needs. Dr. Cheng Kam-chung, Founder and Chairman of the Board of the Foundation, and Liu Liang, Assistant Vice President and General Manager of the Business Unit at Chia Tai Tianqing, attended the signing ceremony. Previously, the "Defu Combination (Anlotinib Hydrochloride Capsules, Benmelstobart Injection)" has already benefited a group of Hong Kong patients through the NPP program. 

Since their first collaboration in March 2025, Chia Tai Tianqing and the Foundation have used the free NPP (Named Patient Program) as a bridge to accelerate the access of innovative drugs from the mainland to Hong Kong patients: in August 2025, the first batch of Anlotinib and Benmelstobart was delivered; in November 2025, the cooperation was expanded to include the first-line treatment of advanced renal cell carcinoma; the inclusion of Culmerciclib into the NPP project this time is another important practice for both parties in deepening the new model of medical charity and responding to Hong Kong's "Good Medicine for Hong Kong" policy. 

Culmerciclib Capsules is a globally first-in-class CDK2/4/6 inhibitor independently developed by Chia Tai Tianqing. It was approved for marketing by the National Medical Products Administration (NMPA) in December 2025, in combination with fulvestrant injection, for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer in patients who have previously received endocrine therapy. Under the NPP cooperation agreement, eligible Hong Kong breast cancer patients can use the drug in compliance after a doctor's evaluation before the drug is registered and launched in Hong Kong, allowing them to benefit from mainland innovation achievements in advance and effectively alleviating the difficulties of drug access and limited choices. 

Liu Liang stated that Sino Biopharm and Chia Tai Tianqing have always been committed to the mission of promoting pharmaceutical innovation and safeguarding patient health, continuously using diverse pathways such as Hong Kong listings and NPP projects to bring good mainland drugs to Hong Kong patients faster. This collaboration allows more Hong Kong patients to use mainland's innovative achievements as early as possible, and also strengthens the medical and health cooperation between the two places. In the future, we will continue to ensure the supply of medicines and explore the possibility of cooperation on more cancer types and more products. 

Dr. Cheng Kam-chung pointed out that the inclusion of Culmerciclib this time will bring more high-quality choices to patients in need in Hong Kong and bring new hope to more families. The Foundation will continue to gather the strength of compassionate partners from all walks of life to allow more high-quality innovative drugs to reach patients directly through the NPP project. From Anlotinib and Benmelstobart to Culmerciclib, Chia Tai Tianqing's Compassionate Corporate Partner NPP program continues to expand, covering the treatment needs of multiple cancer types and full cycles. Driven by the dual wheels of innovation and charity, it has opened a "fast track" for good mainland drugs to enter Hong Kong. 

In the future, Chia Tai Tianqing will continue to work closely with the Greater China Cancer Care Foundation, follow Hong Kong's pro-people pharmaceutical policies, promote the inclusion of more innovative drugs in the cooperation, warm more lives with health technology, and safeguard the health of Hong Kong citizens. 
Compassionate partners, the advisory team, and the board of directors of the Foundation, Pan Quansheng, Assistant Vice President and General Manager of the Business Unit at Chia Tai Tianqing, Zhang Yong, Assistant Vice President and Assistant to the President of the Research Institute, and Li Yanyan, Deputy Director of Marketing for the Cornerstone Business Unit, participated in this event. 

Declaration:

The copyright of this article is owned by the original author or the Company. It may not be used by reprinting, copying, filming, adapting, compiling, or other means without authorization. The portrait rights of the individuals appearing in this article belong to the individuals themselves. Unauthorized use is prohibited.